Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

9/11/24 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ELYM alert in real time by email

SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.

Stifel 2024 Virtual Immunology and Inflammation Summit

Date: Wednesday, September 18, 2024

Format: 1x1 meetings

About Eliem Therapeutics, Inc.

Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia and membranous nephropathy. For more information, please visit https://eliemtx.com/.

Investors

Chris Brinzey

ICR Westwicke

[email protected]

339-970-2843

Get the next $ELYM alert in real time by email

Date	Price Target	Rating	Analyst
9/7/2021	$32.00	Buy	Guggenheim
9/7/2021	$35.00	Buy	Stifel
9/7/2021	$33.00	Outperform	SVB Leerink

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Chat with this insight

Recent Analyst Ratings for $ELYM

$ELYM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ra Capital Management, L.P. was granted 5,259,872 shares and bought $49,952,817 worth of shares (13,008,546 units at $3.84) (SEC Form 4)

$ELYM SEC Filings

SEC Form 8-K filed by Eliem Therapeutics Inc

SEC Form 8-K filed by Eliem Therapeutics Inc

SEC Form 8-K filed by Eliem Therapeutics Inc

$ELYM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Eliem Therapeutics Inc

Amendment: SEC Form SC 13G/A filed by Eliem Therapeutics Inc

SEC Form SC 13G filed by Eliem Therapeutics Inc

$ELYM Leadership Updates

Live Leadership Updates

$ELYM Press Releases

Fastest customizable press release news feed in the world

$ELYM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ELYM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Eliem Therapeutics Reports Second Quarter Financial Results

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Eliem Therapeutics Announces Additions to its Leadership Team

CHIEF ACCOUNTING OFFICER Pimblett Emily converted options into 5,000 shares and sold $9,741 worth of shares (1,191 units at $8.18), increasing direct ownership by 101% to 7,564 units (SEC Form 4)

SEC Form 4 filed by Chief Operating Officer Kaplan Brett

SEC Form 3 filed by new insider Kaplan Brett

Guggenheim initiated coverage on Eliem Therapeutics with a new price target

Stifel initiated coverage on Eliem Therapeutics with a new price target

SVB Leerink initiated coverage on Eliem Therapeutics with a new price target

$ELYM Financials

Live finance-specific insights

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

$ELYM Market Insights

Live Market Insights

IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday

Eliem Therapeutics Files Prospectus Relates To Resale From Time To Time Of Up To 36.8M Shares Of Common Stock By Selling Stockholders

Eliem Therapeutics Announces Its Addition To The Russell 2000 And Russell 3000 Indexes, , Effective Today

Recent Analyst Ratings for
$ELYM

$ELYM
Insider Purchases

$ELYM
SEC Filings

$ELYM
Large Ownership Changes

$ELYM
Leadership Updates

$ELYM
Press Releases

$ELYM
Insider Trading

$ELYM
Analyst Ratings

$ELYM
Financials

$ELYM
Market Insights